MEDSIR, a leading international company in oncology research, has announced the results of the PHERGuide study during the 2025 San Antonio Breast Cancer Symposium (SABCS). This research, presented as ...

The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...

Drug developers increasingly are harnessing AI to optimise clinical trial patient selection and to interpret results to ...

Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration ...

USA: AI-augmented screening shows promise in improving the identification of patients with transthyretin amyloid ...

Scientists identified cellular metabolism and energy signaling as a central factor connecting genetic and environmental ...

New trials highlight Pathlight’s performance in the neoadjuvant triple-negative breast cancer (TNBC) settingMORRISVILLE, N.C.--(BUSINESS WIRE)--#BreastCancer--SAGA Diagnostics®, a pioneer in ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...

Dr Catherine Elliott of Cancer Research UK explores how vaccine advances could transform cancer prevention and treatment ...

Today at the San Antonio Breast Cancer Symposium (SABCS), researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and ...

Bioptimus, the leader in AI models for biology, today announced a major leap forward with the unveiling of M-Optimus, the first model that combines multiple biological modalities, designed to simulate ...

From delivering life-saving medical devices to transforming ancient architecture and preparing for flight on Mars, a new ...